Eric J Kim1, Weijie V Lin2, Sean M Rodriguez2, Ariel Chen3, Asad Loya2, Christina Y Weng4. 1. Cullen Eye Institute, Baylor College of Medicine, 1977 Butler Blvd., Houston, TX, 77030, USA. 2. School of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. 4. Cullen Eye Institute, Baylor College of Medicine, 1977 Butler Blvd., Houston, TX, 77030, USA. christina.weng@bcm.edu.
Abstract
PURPOSE OF REVIEW: Diabetes mellitus is a global epidemic which is growing in prevalence, and diabetic macular edema (DME) is a leading cause of visual impairment among patients affected by this disease. Our objective is to review current and upcoming therapeutic approaches to DME. RECENT FINDINGS: Once considered the gold standard in treatment of DME, focal/grid laser is now reserved mostly for non-center-involving DME, while anti-vascular endothelial growth factor (anti-VEGF) therapy has become the first-line treatment. However, suboptimal responders to anti-VEGF and the burden of frequent injections have stimulated the development of novel approaches. Corticosteroids can be effective in treating DME, but adverse effects such as intraocular pressure elevation and cataract formation must be considered. Emerging therapeutics and drug delivery systems in the pipeline offer exciting potential solutions to this vision-threatening disease. Multiple types of therapeutics targeting various pathways implicated in the pathogenesis of DME may help lessen the global burden of vision loss from diabetes.
PURPOSE OF REVIEW: Diabetes mellitus is a global epidemic which is growing in prevalence, and diabetic macular edema (DME) is a leading cause of visual impairment among patients affected by this disease. Our objective is to review current and upcoming therapeutic approaches to DME. RECENT FINDINGS: Once considered the gold standard in treatment of DME, focal/grid laser is now reserved mostly for non-center-involving DME, while anti-vascular endothelial growth factor (anti-VEGF) therapy has become the first-line treatment. However, suboptimal responders to anti-VEGF and the burden of frequent injections have stimulated the development of novel approaches. Corticosteroids can be effective in treating DME, but adverse effects such as intraocular pressure elevation and cataract formation must be considered. Emerging therapeutics and drug delivery systems in the pipeline offer exciting potential solutions to this vision-threatening disease. Multiple types of therapeutics targeting various pathways implicated in the pathogenesis of DME may help lessen the global burden of vision loss from diabetes.
Authors: Emmett T Cunningham; Anthony P Adamis; Michael Altaweel; Lloyd P Aiello; Neil M Bressler; Donald J D'Amico; Mauro Goldbaum; David R Guyer; Barrett Katz; Manju Patel; Steven D Schwartz Journal: Ophthalmology Date: 2005-10 Impact factor: 12.079
Authors: Marco A Bonini-Filho; Rodrigo Jorge; José C Barbosa; Daniela Calucci; Jose A Cardillo; Rogério A Costa Journal: Invest Ophthalmol Vis Sci Date: 2005-10 Impact factor: 4.799
Authors: Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti Journal: Bull World Health Organ Date: 2004-12-14 Impact factor: 9.408
Authors: Helena Giannakaki-Zimmermann; Alexandra Behrndt; Laura Hoffmann; Maria-Magdalena Guichard; Cengiz Türksever; Christian Prünte; Katja Hatz Journal: Ophthalmic Res Date: 2021-01-26 Impact factor: 2.892
Authors: Kyle Battiston; Ian Parrag; Matthew Statham; Dimitra Louka; Hans Fischer; Gillian Mackey; Adam Daley; Fan Gu; Emily Baldwin; Bingqing Yang; Ben Muirhead; Emily Anne Hicks; Heather Sheardown; Leonid Kalachev; Christopher Crean; Jeffrey Edelman; J Paul Santerre; Wendy Naimark Journal: Nat Commun Date: 2021-05-17 Impact factor: 14.919
Authors: Carlos D Nuñez-Amaro; Aura Ileana Moreno-Vega; Elva Adan-Castro; Magdalena Zamora; Renata Garcia-Franco; Paulina Ramirez-Neria; Marlon Garcia-Roa; Yolanda Villalpando; Juan Pablo Robles; Gabriela Ramirez-Hernandez; Mariana Lopez; Jorge Sanchez; Ellery Lopez-Star; Thomas Bertsch; Gonzalo Martinez de la Escalera; Ma Ludivina Robles-Osorio; Jakob Triebel; Carmen Clapp Journal: Transl Vis Sci Technol Date: 2020-08-17 Impact factor: 3.283